Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr3.04
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr3.04
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr4.07
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr183.45M
Enterprise Valuekr121.90M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Pipeline In Sexual & Reproductive HealthA narrow, clinical-stage focus on sexual and reproductive health and small-molecule programs creates durable strategic clarity. Targeting defined unmet needs improves partnerability and commercialization prospects, concentrating R&D resources and raising long-term value if trials succeed.
Modest Financial LeverageVery low debt reduces solvency and interest-rate risk, preserving flexibility to pursue partnerships or equity financing rather than costly borrowings. Modest leverage is a durable strength for a cash-burning biotech, improving resilience during clinical development cycles.
Free Cash Flow Improved Relative To Prior YearAn improvement in free cash flow and FCF being materially less negative than net income indicates better cash management or lower non-cash charges. This trend, if sustained, can extend runway, make the company more attractive to partners, and reduce near-term financing pressure.
Bears Say
Pre-revenue With Widening LossesPersisting as a pre-revenue entity with materially wider losses erodes capital and amplifies funding needs. Over a 2–6 month horizon this structural loss profile raises the probability of dilution and constrains ability to self-fund development milestones absent partnerships or financing.
Sustained High Operating Cash BurnPersistent negative operating cash flow near -18M annually is a structurally durable constraint that will require external funding to maintain development programs. High cash burn limits strategic optionality and increases dilution risk if financing is needed within the medium term.
Declining Equity And Negative Returns On EquityA substantial drop in equity alongside a negative ROE signals capital destruction from operations. This durable weakness undermines investor confidence, raises likelihood of future equity raises, and compresses long-term shareholder value absent a clear pathway to profitability or successful partnering.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.53 and its highest was kr4.07 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr183.45M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 41 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.